NCT01396317 - Study of Tocilizumab to Treat Polymyalgia Rheumatica | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

December 31, 2015

Study Completion Date

January 31, 2016

Conditions

Polymyalgia Rheumatica (PMR)

Interventions

DRUG

Tocilizumab

Tocilizumab is a humanized anti-interleukin-6 receptor antibody that has been FDA approved for the treatment of rheumatoid arthritis (RA). This molecule binds to the IL-6 binding site of human IL-6 receptor, and competitively inhibits IL-6 signaling.

Trial Locations (1)

100214898

Hospital for Special Surgery, New York